Communiqués Replimune Group, Inc.

Actions

REPL

US76029N1063

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 16:31:23 18/09/2026			Varia. 5j.	Varia. 1 janv.
12,94 ^USD	+0,58%		-0,54%	+32,20%

15/09	Transcript : Replimune Group, Inc. - Shareholder/Analyst Call
19/08	Trump choisit Heidi Overton, conseillère à la Maison-Blanche, pour diriger la FDA, selon une source	RE

Communiqués

03/09	Replimune to Present at the Cantor Global Healthcare Conference 2026	AQ
19/08	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
14/08	Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update	AQ
14/08	INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - REPL	BU
10/08	Replimune Announces Pricing of $150 Million Underwritten Offering	AQ
06/08	Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen	AQ
29/06	Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update	AQ
26/06	Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma	AQ
31/05	Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting	AQ
30/05	Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting	GL
29/05	Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA	AQ
27/04	Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
23/04	Replimune : RP1 + Nivolumab in Patients with NMSC at EADO 2026	PU
23/04	Replimune : RP1 + Nivolumab in Patients with Anti–PD-1–Failed Melanoma at EADO 2026	PU
13/04	Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma	AQ
10/04	Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma	AQ
02/03	Replimune to Present at Two Upcoming Investor Conferences	AQ
03/02	Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update	AQ
14/01	Replimune : JP Morgan Healthcare Conference 2026 Presentation	PU
18/12	Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
07/11	Replimune : IGNYTE Trial Biomarker and Updated Clinical Data Presentation at SITC 2025	PU
07/11	Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)	AQ
07/11	Replimune : RP1 + Nivolumab in Patients with Advanced Anti–PD-1–Failed Melanoma at SITC 2025	PU
07/11	Replimune : RP1 + Nivolumab in Patients with and without prior BRAF-Directed Therapy at SITC 2025	PU
06/11	Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update	AQ